Mineralys Therapeutics CEO Jon Congleton Sells $291,441 in Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton executed a sale of 10,700 shares of the company's common stock on July 13, 2026, totaling $291,441. The transaction, conducted through a Rule 10b5-1 trading plan adopted in January 2025, saw shares sold at prices between $26.80 and $27.58. This sale reduces Congleton's direct holdings but…